Risk-reducing decisions regarding germline BRCA pathogenic variant: focusing on the timing of genetic testing and RRSO.

Autor:	Abe A; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan akiko.abe@jfcr.or.jp., Nomura H; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Fusegi A; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Yunokawa M; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Ueki A; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Habano E; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Arakawa H; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Kaneko K; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Minoura Y; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Inari H; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Ueno T; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Kanao H; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Jazyk:	angličtina
Zdroj:	Journal of medical genetics [J Med Genet] 2024 Mar 21; Vol. 61 (4), pp. 392-398. Date of Electronic Publication: 2024 Mar 21.
DOI:	10.1136/jmg-2023-109549
Abstrakt:	Background: In Japan, the public insurance policy was revised in 2020 to cover hereditary breast and ovarian cancer (HBOC), including genetic testing and surveillance, for patients with breast cancer (BC). Consequently, the demand for risk-reducing salpingo-oophorectomy (RRSO) has increased. This study aimed to clarify the changes in the demand and timing of genetic testing and RRSO associated with public insurance coverage for HBOC in Japan. Methods: This retrospective analysis included 350 women with germline BRCA (g BRCA ) pathogenic variants (PVs) who had visited gynaecologists; they received g BRCA genetic testing at 45.1±10.6 (20-74) years. The use of medical testing and preventive treatment was compared between the preinsurance and postinsurance groups using Mann-Whitney U and Fisher's exact tests. Results: The findings indicate that RRSO rates doubled from 31.4% to 62.6% among patients with g BRCA -PV. The implementation rate was 32.4% among unaffected carriers and 70.3% among BC-affected patients. Younger patients received genetic testing with significantly shorter intervals between BC diagnosis and genetic testing and between genetic testing and RRSO. Conclusion: Overall, the insurance coverage for HBOC patients with BC has increased the frequency of RRSO in Japan. However, a comparison between the number of probands and family members indicated that the diagnosis among family members is inadequate. The inequality in the use of genetic services by socioeconomic groups is an issue of further concern. Competing Interests: Competing interests: None declared. (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu